211 related articles for article (PubMed ID: 28409559)
1. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Wang HW; Xu ZK; Song Y; Liu YG
Cancer Gene Ther; 2017 May; 24(5):215-220. PubMed ID: 28409559
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
3. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Fan CH; Liu WL; Cao H; Wen C; Chen L; Jiang G
Cell Death Dis; 2013 Oct; 4(10):e876. PubMed ID: 24157870
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
5. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Ochsenbein AF; Schubert AD; Vassella E; Mariani L
J Neurooncol; 2011 Jun; 103(2):343-51. PubMed ID: 20857319
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
8. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Fukushima T; Takeshima H; Kataoka H
Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
[TBL] [Abstract][Full Text] [Related]
9. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
[TBL] [Abstract][Full Text] [Related]
10. Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease.
Kubota Y; Aoki Y; Masaki N; Obara K; Hamada K; Han Q; Bouvet M; Tsunoda T; Hoffman RM
Biochem Biophys Res Commun; 2024 Feb; 695():149418. PubMed ID: 38176171
[TBL] [Abstract][Full Text] [Related]
11. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Munisamy M; Munisamy S; Kumar JP; Jose A; Thomas L; Baburaj G; Subbiah V
Pharmacogenomics J; 2021 Apr; 21(2):262-272. PubMed ID: 33589792
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
16. Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
Jiang G; Jiang AJ; Xin Y; Li LT; Cheng Q; Zheng JN
Mol Biol Rep; 2014 Oct; 41(10):6659-65. PubMed ID: 24990698
[TBL] [Abstract][Full Text] [Related]
17. [Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Zhang JP; Shi HL; Sai K; Yue WY; Mu YG; Zhang XH; Chen ZP
Ai Zheng; 2006 Dec; 25(12):1533-7. PubMed ID: 17166381
[TBL] [Abstract][Full Text] [Related]
18. Impact of temozolomide on immune response during malignant glioma chemotherapy.
Sengupta S; Marrinan J; Frishman C; Sampath P
Clin Dev Immunol; 2012; 2012():831090. PubMed ID: 23133490
[TBL] [Abstract][Full Text] [Related]
19. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
20. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
